Patents by Inventor Kenneth Brunson

Kenneth Brunson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMTIMICROBIAL SILICONES
    Publication number: 20240123122
    Abstract: A composition, comprising: a physiologically-acceptable polydimethylsiloxane having a surface; and one or more normal C6-C20NR1R2 saturated amine, salt thereof, or combination thereof, in contact with the polydimethylsiloxane, the surface, or both, wherein R1 and R2 may be same or different and independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, or combination thereof
    Type: Application
    Filed: May 24, 2023
    Publication date: April 18, 2024
    Applicant: WynnVision, LLC
    Inventors: Kenneth J. WYNNE, Olga ZOLOTARSKAYA, Rebecca JARRELL, Kennard BRUNSON, Chenyu WANG
  • Anti-Angiogenic Peptides and Methods of Use Thereof
    Publication number: 20080207502
    Abstract: Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides maybe used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF, or integrin activation of endothelial cells in angiogenesis-associated diseases such as cancer, leukemia, multiple myeloma, inflammatory diseases, eye diseases and skin disorders.
    Type: Application
    Filed: October 14, 2005
    Publication date: August 28, 2008
    Applicant: SOPHERION THERAPEUTICS, INC.
    Inventors: Luca Rastelli, Judith Landin, Uriel Malyankar, Richard Kitson, Melissa Corso, Kenneth Brunson
  • Anti-angiogenic peptides and methods of use thereof
    Publication number: 20060172941
    Abstract: Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF, or integrin activation of endothelial cells in angiogenesis-associated diseases such as cancer, leukemia, multiple myeloma, inflammatory diseases, eye diseases and skin disorders.
    Type: Application
    Filed: January 9, 2006
    Publication date: August 3, 2006
    Inventors: Luca Rastelli, Judith Landin, Uriel Malyankar, Richard Kitson, Melissa Corso, Kenneth Brunson